<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03423849</url>
  </required_header>
  <id_info>
    <org_study_id>ShandongCHI-04</org_study_id>
    <nct_id>NCT03423849</nct_id>
  </id_info>
  <brief_title>The Maintenance Regimen and Revised Regimen for Advanced Breast Cancer Survivors After First-line Salvage Therapy</brief_title>
  <official_title>Prospective Randomized Controlled Study of the Maintenance Regimen and Revised Regimen for Advanced Breast Cancer Survivors After First-line Salvage Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhiyong Yu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shandong Cancer Hospital and Institute</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Worldwide, breast cancer is the most incident and prevalent cancer among women. Despite&#xD;
      advances in the treatment of advanced breast cancer (ABC) during the past decade, adjuvant&#xD;
      systemic therapy has yield little progression for such patients. ABC remains an incurable&#xD;
      disease, responsible for approximate 40,000 deaths annually and a median life expectancy of&#xD;
      no more than 3 years. The NCCN guidelines clearly define routine adjuvant chemotherapy&#xD;
      regimens for the early breast cancer, however, for the patients with recurrence and&#xD;
      metastasis, the choice of treatment options is not clear. In this trial, we choose the&#xD;
      patients with disease progression who received anthracycline and taxane adjuvant chemotherapy&#xD;
      after surgery. The patients received vinorelbine and gemcitabine (NG) or vinorelbine and&#xD;
      platinum (NP) regiments for 6 cycles. Then the patients with complete response (CR), partly&#xD;
      response (PR) and stable disease(SD) will be assigned to 3 groups, one group will receive the&#xD;
      original regiment for 3 cycles to maintain treatment, one group will receive the vinorelbine&#xD;
      for 6 cycles, the other group will receive the capecitabine for 6 cycles. Trasuzumab will be&#xD;
      used to patients if HER-2 positive. Endocrine therapy will be used if the hormone receptors&#xD;
      positive after the chemotherapy. The primary endpoint is to assess disease-free survival&#xD;
      (DFS), the secondary endpoint is to assess the overall survival (OS).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The trial is designed to help us to choose the maintain treatment regiment for the patients&#xD;
      with effective first-line salvage therapy. After inorelbine and gemcitabine (NG) or&#xD;
      vinorelbine and platinum (NP) regiments for 6 cycles, patients will be assess the effect of&#xD;
      treatment. As for the patients with complete response (CR), partly response (PR) and stable&#xD;
      disease(SD), the investigators will randomly assign them to receive 3 cycles of original&#xD;
      regiment, or 6 cycles of vinorelbine, or 6 cycles of capecitabine. Trasuzumab will be used to&#xD;
      patients if HER-2 positive. Endocrine therapy will be used if the hormone receptors positive&#xD;
      after the chemotherapy. The effectiveness of therapy will be estimated after the maintain&#xD;
      therapy. The first two years the patient was prescribed every 3 months to review the disease,&#xD;
      then review the disease every six months. The primary endpoint is to assess disease-free&#xD;
      survival (DFS), the secondary endpoint is to assess the overall survival (OS).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">February 8, 2018</start_date>
  <completion_date type="Anticipated">February 8, 2020</completion_date>
  <primary_completion_date type="Anticipated">February 8, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free survival (DFS)</measure>
    <time_frame>5 years</time_frame>
    <description>To determine the percentage of disease-free survival (DFS) for the The original program (NG/NP) or One of the original program (N) or Capecitabine monotherapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>5 years</time_frame>
    <description>To determine the percentage of Overall survival (OS) for the The original program (NG/NP) or One of the original program (N) or Capecitabine monotherapy</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Chemotherapy Effect</condition>
  <condition>Disease-free Survival</condition>
  <arm_group>
    <arm_group_label>The original program (NG/NP)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vinorelbine injection 25mg/m2 on day 1 and day 8, Gemcitabine injection 1250mg/m2 on day1 and day 8,every 3 weeks for 3 cycles（for the patients who used the NG salvage therapy） or Vinorelbine injection 25mg/m2 on day 1 and day 8,Cisplatin injection 25mg/m2 on day1,every 3 weeks for 3 cycles（for the patients who used the NP salvage therapy ）</description>
  </arm_group>
  <arm_group>
    <arm_group_label>One of the original program (N)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vinorelbine injection,25mg/m2 on day 1 and day 8,every 3 weeks for 6 cycles. or, Vinorelbine oral 60mg/m2 on day 1,every week for 6 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Capecitabine monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Capecitabine oral 1250mg/m2,bid,for 6 cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinorelbine</intervention_name>
    <description>25mg/m2,day 1 and day 8, every 3 weeks</description>
    <arm_group_label>One of the original program (N)</arm_group_label>
    <arm_group_label>The original program (NG/NP)</arm_group_label>
    <other_name>Anhydmvinblastine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>1250mg/m2,day 1 and day 8, every 3 weeks</description>
    <arm_group_label>The original program (NG/NP)</arm_group_label>
    <other_name>Gemcel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>25mg/m2,day 1,every 3 weeks</description>
    <arm_group_label>The original program (NG/NP)</arm_group_label>
    <other_name>cisplatinum</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>1250mg/m2,day 1 to day 14, every 3 weeks</description>
    <arm_group_label>Capecitabine monotherapy</arm_group_label>
    <other_name>XELODA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All patients were required to give written informed consent.&#xD;
&#xD;
          -  Patients with distant metastasis who primary received anthracycline and taxane&#xD;
             adjuvant chemotherapy after surgery.&#xD;
&#xD;
          -  After inorelbine and gemcitabine (NG) or vinorelbine and platinum (NP) regiments for 6&#xD;
             cycles,patients were assessed the effect of treatment. As for the patients with&#xD;
             complete response (CR), partly response (PR) and stable disease(SD).&#xD;
&#xD;
          -  Have normal cardiac functions by echocardiography&#xD;
&#xD;
          -  ECOG scores are ≤ 0-1.&#xD;
&#xD;
          -  Patients are disposed to practice contraception during the whole trial.&#xD;
&#xD;
          -  The results of patients' blood tests are as follows:&#xD;
&#xD;
        Hb ≥ 90 g/L WBC ≥ 3.0×109/L Plt ≥ 100×109/L Neutrophils ≥ 1.5×109/L ALT and AST ≤ 2.5 times&#xD;
        of normal upper limit. TBIL ≤ 1.5 times of normal upper limit. Creatinine ≤ 1.5 times of&#xD;
        normal upper limit.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have other cancers at the same time or have the history of other cancers in recent&#xD;
             five years, excluding the controlled skin basal cell carcinoma or skin squamous cell&#xD;
             carcinoma or carcinoma in situ of cervix.&#xD;
&#xD;
          -  Active infections.&#xD;
&#xD;
          -  Severe non-cancerous diseases.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhiyong Yu, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Shandong Cancer Hospital and Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zhaoyun Liu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shandong Cancer Hospital and Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhiyong Yu, PhD</last_name>
    <phone>86-13355312277</phone>
    <email>drzhiyongyu@aliyun.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhaoyun Liu, MD</last_name>
    <phone>86-17865123967</phone>
    <email>liuzhaoyun99@163.com</email>
  </overall_contact_backup>
  <verification_date>February 2018</verification_date>
  <study_first_submitted>January 1, 2018</study_first_submitted>
  <study_first_submitted_qc>February 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 6, 2018</study_first_posted>
  <last_update_submitted>February 5, 2018</last_update_submitted>
  <last_update_submitted_qc>February 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Shandong Cancer Hospital and Institute</investigator_affiliation>
    <investigator_full_name>Zhiyong Yu</investigator_full_name>
    <investigator_title>Director of the Breast Surgery Ⅰ</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

